Avanos Medical (AVNS) Stock Price, News & Analysis

Written before these shares stopped trading.

Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company that develops, manufactures and markets medical device solutions for healthcare providers and patients. According to company disclosures, Avanos focuses on delivering clinically superior medical device solutions that help patients "get back to the things that matter." The company is headquartered in Alpharetta, Georgia, and its shares trade on the New York Stock Exchange under the symbol AVNS.

Avanos states that it is committed to addressing important healthcare needs in two main areas: providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Across its portfolio, Avanos reports that it develops recognized brands, markets them globally and holds leading market positions in multiple product categories.

Business focus and segments

Based on its public financial reporting, Avanos organizes its operations into two primary segments: Specialty Nutrition Systems ("SNS") and Pain Management & Recovery ("PM&R"). These segments reflect the company’s emphasis on nutrition support and opioid-sparing pain management.

The Specialty Nutrition Systems segment is described as a life-sustaining business that delivers nutrition support. Avanos reports that SNS net sales are driven by demand across enteral feeding and neonate solutions categories. Within SNS, the company highlights strong demand for long-term feeding products and growth in short-term feeding offerings, including expansion of its US CORTRAK standard of care offerings. Avanos characterizes SNS as delivering above-market results in its recent financial periods, with volume growth supported by continued strong demand.

The Pain Management & Recovery segment focuses on opioid-sparing pain management and recovery solutions that support patients as they move from surgery to recovery. Within PM&R, Avanos reports radiofrequency ablation ("RFA") solutions, surgical pain products and recovery product lines. The company notes that RFA product net sales have grown, with momentum in RFA generator sales leading to higher procedure volumes. At the same time, Avanos has reported lower volume in certain surgical pain and recovery product lines and has indicated that some revenue streams in this area were strategically not pursued in a given year.

Strategic transformation and portfolio shaping

Avanos describes itself as undergoing an ongoing transformation focused on advancing its strategic SNS and PM&R segments. As part of this transformation, the company has engaged in both divestitures and acquisitions to align its portfolio with these priorities.

On the divestiture side, Avanos announced the sale of its Hyaluronic Acid ("HA") product line, including TriVisc and GenVisc 850 injection products indicated for the treatment of osteoarthritis pain in the knee, to Channel-Markers Medical, LLC. The company states that this divestiture is intended to align its product portfolio more closely with its strategic priorities in Pain Management & Recovery and Specialty Nutrition Systems, and to reinforce its focus on areas where it sees the greatest potential to lead and deliver long-term value.

Avanos has also entered into an agreement with WRS Group, LLC for WRS to acquire substantially all assets and rights related to Avanos’ US Game Ready orthopedic rental business. Under this agreement, WRS will assume ownership of the Game Ready US orthopedic rental assets, while Avanos will continue to manufacture and supply Game Ready systems and accessories and provide transition support for a defined period. The companies also plan a long-term distribution and supply agreement covering the orthopedic and patient segments of the US business. Avanos characterizes this partnership as consistent with its strategy of focusing on core strengths while collaborating with partners to extend the reach of its medical technologies.

On the acquisition side, Avanos announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas. Nexus is described as the maker of the proprietary TKO anti-reflux needleless connector technology, which is designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including Neonatal and Pediatric Intensive Care Units (NICUs and PICUs). Avanos states that the Nexus acquisition adds complementary technology to its Specialty Nutrition Systems business and reinforces its focus on safe, reliable therapy delivery for neonatal patient populations. The company indicates that the Nexus TKO technology is expected to deliver immediate value in NICU and PICU care.

Clinical focus: nutrition support and opioid-sparing care

In its public descriptions, Avanos emphasizes two central clinical themes. First, the company highlights providing a "vital lifeline for nutrition" for patients across care settings, from hospital to home. This focus is reflected in its Specialty Nutrition Systems segment, which includes enteral feeding and neonate solutions and, following the Nexus acquisition, anti-reflux needleless connector technology intended to support consistent nutrition and medication delivery in critical care environments.

Second, Avanos places emphasis on reducing the use of opioids while helping patients move from surgery to recovery. This theme underpins the Pain Management & Recovery segment, which includes radiofrequency ablation solutions and surgical pain and recovery product lines designed to support opioid-sparing pain management strategies. The company has described its RFA product lines, including ESENTEC and TRIDENT, as contributing to more procedures and supporting its goal of helping patients get back to the things that matter.

Geographic reach and market positioning

Avanos reports that it develops, manufactures and markets its recognized brands globally. The company states that it holds leading market positions in multiple categories across its portfolio, though it does not specify particular rankings or shares in the provided materials. Its disclosures indicate that its products are used in hospital and critical care settings and that certain therapies, particularly in nutrition, extend into home-based care.

Organizational developments and governance

Recent SEC filings and press releases describe several organizational and governance developments. Avanos has announced executive appointments, including a senior vice president and chief financial officer and a senior vice president and chief human resources officer, as well as the appointment of its chief executive officer to the board of directors. The company has also reported an organizational restructuring that eliminated certain senior positions, with responsibilities reallocated among other employees, and has detailed the associated severance and equity treatment under its established plans.

These disclosures indicate an ongoing effort to align leadership and organizational structure with the company’s transformation priorities in its core SNS and PM&R segments.

Financial reporting and non-GAAP measures

Through its quarterly earnings releases and related Form 8-K filings, Avanos provides net sales, segment performance and profitability metrics. The company reports net sales and operating results for its Specialty Nutrition Systems and Pain Management & Recovery segments, as well as corporate and other activities. It has also disclosed a non-cash goodwill impairment charge in the PM&R segment following an assessment triggered by downward pressure on its market capitalization.

In addition to GAAP metrics, Avanos presents a set of non-GAAP financial measures, including adjusted gross and operating income, adjusted income before taxes, adjusted effective tax rate, adjusted net income, adjusted diluted earnings per share, adjusted selling, general and administrative expenses, adjusted EBITDA and free cash flow. The company explains that these measures exclude items such as acquisition and integration charges, restructuring and transformation expenses (including divestiture-related costs), EU Medical Device Regulation compliance expenses, amortization of acquisition-related intangibles, impairments, certain tax effects and currency impacts. Avanos states that management and the board use these non-GAAP measures to evaluate performance, allocate resources and set incentive compensation goals.

Investor communications

Avanos regularly communicates with investors through earnings press releases, conference calls and presentations at healthcare conferences. The company has filed Form 8-Ks to furnish earnings releases and to disclose participation in events such as the J.P. Morgan Healthcare Conference, where it presents slide materials about its business and strategy. These communications provide updates on segment performance, transformation progress, portfolio changes and financial guidance ranges.